Trial Profile
SAFETY, TOLERABILITY AND POTENTIAL THERAPEUTIC EFFICACY OF A NOVEL GLUTAMATE MODULATOR AS ADJUNCTIVE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jul 2013
Price :
$35
*
At a glance
- Drugs ADX 71149 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- 04 Jul 2013 New trial record
- 18 May 2013 Results presented at the 166th Annual Meeting of the American Psychiatric Association.